Evidence map›Paper›PMID 42388654›Full record

ArticleFood science & nutrition2026

3'-Sialyllactose Prevents Atherosclerosis by Attenuating Chronic Inflammation via the Gut-Immune-Cardiovascular Axis in

Yingying Zhuang, Wei Zhang, Linlin Zhou, Hui Shu, Wenqing Bo, Yiding Wang, Xinyuan Huang, Xinning Zhao, Hanying Zheng, Dongbei Guo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yingying ZhuangDepartment of Clinical Nutrition, Zhongshan Hospital (Xiamen) Fudan University Xiamen China.
Wei ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Linlin ZhouState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Hui ShuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Wenqing BoXiamen Key Laboratory of Biotherapy Xiamen China.
Yiding WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Xinyuan HuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Xinning ZhaoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Hanying ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Dongbei GuoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Xiaoxuan ChenState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Lili PanState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.
Hongwei LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University Xiamen China.ORCID https://orcid.org/0000-0003-2789-5281
Xinyue WangDepartment of Clinical Nutrition, Zhongshan Hospital (Xiamen) Fudan University Xiamen China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3'-sialyllactose (3'-SL) has demonstrated potential in regulating glycolipid metabolism and improving intestinal immunity, thereby exhibiting anti-atherosclerotic (AS) properties. However, the mechanism by which 3'-SL exerts its anti-AS effects through the regulation of inflammatory signaling via intestinal immunity remains unknown. Herein, 40 male low-density lipoprotein receptor knockout (

Indexed as

3′‐sialyllactoseatherosclerosischronic inflammationgut‐immune‐cardiovascular axishigh‐cholesterol dietlow‐density lipoprotein receptor knockout mice

Identifiers

PMID42388654
PMCPMC13320821

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.